Celldex Adds $40M Publicly for Immunotherapy Pipeline
Nearly three months into its pivotal study of lead immunotherapy candidate rindopepimut in a subset of glioblastoma multiforme (GBM) patients, Celldex Therapeutics Inc. is pulling in about $40.4 million in a public offering to help support that study and advance earlier pipeline programs.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter